Clene Inc.
NASDAQ: CLNN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert Etherington
- Employees
- 75
- Headquarters
- Salt Lake City, United States
- IPO year
- 2018
- Market cap
- $59.2M
- Website
- https://clene.com
Loading CLNN…
Loading profile data…Frequently asked questions about CLNN
What does Clene Inc. (CLNN) do?
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a...
Where does CLNN trade?
Clene Inc. (CLNN) trades on the NASDAQ Capital Market.
What sector is CLNN in?
Clene Inc. (CLNN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Clene Inc.?
Robert Etherington is the chief executive officer of Clene Inc. (CLNN).
Where is Clene Inc. headquartered?
Clene Inc. is headquartered in United States.
Does CLNN pay a dividend?
Clene Inc. (CLNN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLNN go public?
Clene Inc. (CLNN) completed its initial public offering in 2018.